

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 2280 Session of 2020

INTRODUCED BY T. DAVIS, HILL-EVANS, ULLMAN, McNEILL, BARRAR, JOZWIAK, WARREN, MADDEN, FITZGERALD, QUINN, DONATUCCI, SANCHEZ, GALLOWAY, READSHAW AND DRISCOLL, MARCH 4, 2020

REFERRED TO COMMITTEE ON INSURANCE, MARCH 4, 2020

AN ACT

1 Amending the act of May 17, 1921 (P.L.682, No.284), entitled "An  
 2 act relating to insurance; amending, revising, and  
 3 consolidating the law providing for the incorporation of  
 4 insurance companies, and the regulation, supervision, and  
 5 protection of home and foreign insurance companies, Lloyds  
 6 associations, reciprocal and inter-insurance exchanges, and  
 7 fire insurance rating bureaus, and the regulation and  
 8 supervision of insurance carried by such companies,  
 9 associations, and exchanges, including insurance carried by  
 10 the State Workmen's Insurance Fund; providing penalties; and  
 11 repealing existing laws," in casualty insurance, providing  
 12 for coverage for treatment of pediatric autoimmune  
 13 neuropsychiatric disorders associated with streptococcal  
 14 infections and pediatric acute onset neuropsychiatric  
 15 syndrome.

16 The General Assembly of the Commonwealth of Pennsylvania  
 17 hereby enacts as follows:

18 Section 1. The act of May 17, 1921 (P.L.682, No.284), known  
 19 as The Insurance Company Law of 1921, is amended by adding a  
 20 section to read:

21 Section 635.8. Coverage for Treatment of Pediatric  
 22 Autoimmune Neuropsychiatric Disorders Associated with  
 23 Streptococcal Infections and Pediatric Acute Onset  
 24 Neuropsychiatric Syndrome.--(a) A group or individual policy of

1 health and accident insurance or managed care plan that is  
2 amended, delivered, issued or renewed after the effective date  
3 of this section shall provide coverage for treatment of  
4 pediatric autoimmune neuropsychiatric disorders associated with  
5 streptococcal infection and pediatric acute onset  
6 neuropsychiatric syndrome, including the use of intravenous  
7 immunoglobulin therapy.

8 (b) If, at any time, the United States Secretary of Health  
9 and Human Services, or a successor officer, promulgates rules or  
10 regulations to be published in the Federal Register or publishes  
11 a comment in the Federal Register or issues an opinion,  
12 guidance, or other action that would require the Commonwealth,  
13 under any provision of the Patient Protection and Affordable  
14 Care Act (Public Law 111-148, 124 Stat. 119), including 42  
15 U.S.C. § 18031(d)(3)(B) (relating to affordable choices of  
16 health benefits) or any successor provision, to defray the cost  
17 of any coverage for pediatric autoimmune neuropsychiatric  
18 disorders associated with streptococcal infections and pediatric  
19 acute onset neuropsychiatric syndrome outlined in this section,  
20 then the requirement that an insurer cover pediatric autoimmune  
21 neuropsychiatric disorders associated with streptococcal  
22 infections and pediatric acute onset neuropsychiatric syndrome  
23 is inoperative other than any coverage authorized under section  
24 1902 of the Social Security Act (42 U.S.C. § 1396a), and the  
25 Commonwealth shall not assume any obligation for the cost of  
26 coverage for pediatric autoimmune neuropsychiatric disorders  
27 associated with streptococcal infections and pediatric acute  
28 onset neuropsychiatric syndrome.

29 (c) As used in this section:

30 (1) "Pediatric acute onset neuropsychiatric syndrome" means

1 a clinical diagnosis given to children who have a sudden onset  
2 of neuropsychiatric symptoms, including obsessive-compulsive  
3 disorder and restricted food intake.

4 (2) "Pediatric autoimmune neuropsychiatric disorders  
5 associated with streptococcal infections" means a clinical  
6 diagnosis given to children who develop a sudden onset of  
7 obsessive-compulsive disorder or involuntary purposeless  
8 movements as a result of a streptococcal infection.

9 Section 2. This act shall take effect in 60 days.